MEI Pharma Inc - Rasio total nilai perusahaan marang pendapatan MEIP

Logo perusahaan publik meipharma.com (MEIP)

The potential for acquisition by major players and the success of MEI Pharma, Inc. (MEIP) trials are weighed against the development of safe inhibitors for elderly patients. The EV-to-revenue multiple helps compare these factors, where the mark indicates the market value level. However, the development of the R&D pipeline at the current stage results only in linear cost growth, limiting the business's scalability.

MEI Pharma Inc - Rasio nilai perusahaan marang pendapatan MEIP (periode 04.07.2022 - 20.11.2026)

MEI Pharma Inc - rincian analitis lan metrik utama (MEIP)

Analisis wiwitan perusahaan:meipharma.com MEIP
Sampel barang MEI Pharma

The stability of substance supplies for oncology drugs via the diversified routes of MEI Pharma, Inc. (MEIP) correlates directly with the dynamics of the EV/Revenue multiple. This indicator is calculated as the ratio of enterprise value (EV) to sales volume, excluding the impact of debt load, which allows investors to assess the market value of operating assets and determine the company's resilience to debt service costs.